Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress
NCT ID: NCT02184507
Last Updated: 2014-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
92 participants
INTERVENTIONAL
2013-06-30
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Carbohydrate Loading in Diabetic Type 2 Patients Undergoing CABG Surgery on CPB
NCT06951308
Innovative Strategies For Risk Reduction Following CABG
NCT00462436
Investigation of Myocardial Protection Level With Specific Cardioplegia Methods in Cardiac Surgery
NCT05603429
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
NCT06977230
The Impact of Oral Vitamin C in Prevention for Post Operative Atrial Fibrillation (POAF) in Coronary Artery Bypass Surgery (CABG) Patients
NCT06074367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Consumption of the supplement (a 20 gram pack of the supplement daily) 7 days before surgery and placebo (a pack of starch) 30 days post surgery
2. Consumption of placebo 7 days before surgery and supplement 30 days post surgery
3. Consumption of the supplement 7 days before and 30 days post surgery
4. Consumption of placebo 7 days before and 30 days post surgery One week before, before the onset of the surgery, after the surgery, 1 week after and 4 weeks after the operation, blood samples were taken and the levels of hemoglobin A1C, glucose, insulin and malondialdehyde were measured. Also, body composition indices were assessed in four times: one week before the surgery, before the onset of the surgery, 1 week after and 4 weeks after the surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supplement pre CABG
Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
Supplement pre CABG
One sachet of the supplement was consumed daily for 7 days before surgery.
Supplement post CABG
Consumption of placebo 7 days before surgery and supplement 30 days post surgery
Supplement post CABG
One sachet of the supplement was consumed daily for 30 days after surgery
Supplement pre and post CABG
Consumption of the supplement 7 days before and 30 days post surgery
Supplement pre and post CABG
One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
Placebo
Consumption of placebo 7 days before and 30 days post surgery
Placebo
One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supplement pre CABG
One sachet of the supplement was consumed daily for 7 days before surgery.
Supplement post CABG
One sachet of the supplement was consumed daily for 30 days after surgery
Supplement pre and post CABG
One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
Placebo
One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing coronary artery bypass grafting surgery
Exclusion Criteria
* Taking antioxidant supplements
* Cases for emergency operations
* Ejection Fraction \< 30%
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Mohammad Hassan Eftekhari
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Hassan Eftekhari
Professor. PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammad Hassan Eftekhari, professor
Role: STUDY_DIRECTOR
Shiraz University of Medical Sciences
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
91-6447
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.